PE20020291A1 - Profarmacos para ligandos del receptor nmda - Google Patents

Profarmacos para ligandos del receptor nmda

Info

Publication number
PE20020291A1
PE20020291A1 PE2001000820A PE2001000820A PE20020291A1 PE 20020291 A1 PE20020291 A1 PE 20020291A1 PE 2001000820 A PE2001000820 A PE 2001000820A PE 2001000820 A PE2001000820 A PE 2001000820A PE 20020291 A1 PE20020291 A1 PE 20020291A1
Authority
PE
Peru
Prior art keywords
piperidin
hydroxy
formula
pro
drugs
Prior art date
Application number
PE2001000820A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fischer
Joerg Huwyler
Emmanuel Pinard
Rene Wyler
Georg Jaeschke
Marie-Paule Heitz Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020291A1 publication Critical patent/PE20020291A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PE2001000820A 2000-08-21 2001-08-16 Profarmacos para ligandos del receptor nmda PE20020291A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
PE20020291A1 true PE20020291A1 (es) 2002-04-17

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000820A PE20020291A1 (es) 2000-08-21 2001-08-16 Profarmacos para ligandos del receptor nmda

Country Status (35)

Country Link
US (1) US6407235B1 (cg-RX-API-DMAC7.html)
EP (1) EP1313703B1 (cg-RX-API-DMAC7.html)
JP (1) JP4162991B2 (cg-RX-API-DMAC7.html)
KR (1) KR100589991B1 (cg-RX-API-DMAC7.html)
CN (1) CN1227230C (cg-RX-API-DMAC7.html)
AR (1) AR030373A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386022T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001285894B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113348A (cg-RX-API-DMAC7.html)
CA (1) CA2419279C (cg-RX-API-DMAC7.html)
CY (1) CY1107937T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303319B6 (cg-RX-API-DMAC7.html)
DE (1) DE60132782T2 (cg-RX-API-DMAC7.html)
DK (1) DK1313703T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034489A (cg-RX-API-DMAC7.html)
EG (1) EG24293A (cg-RX-API-DMAC7.html)
ES (1) ES2299508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030125B1 (cg-RX-API-DMAC7.html)
HU (1) HU229802B1 (cg-RX-API-DMAC7.html)
IL (1) IL154254A0 (cg-RX-API-DMAC7.html)
JO (1) JO2289B1 (cg-RX-API-DMAC7.html)
MA (1) MA26947A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001311A (cg-RX-API-DMAC7.html)
MY (1) MY136065A (cg-RX-API-DMAC7.html)
NO (1) NO324941B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523990A (cg-RX-API-DMAC7.html)
PA (1) PA8525601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020291A1 (cg-RX-API-DMAC7.html)
PL (1) PL204215B1 (cg-RX-API-DMAC7.html)
PT (1) PT1313703E (cg-RX-API-DMAC7.html)
RS (1) RS51467B (cg-RX-API-DMAC7.html)
RU (1) RU2272027C2 (cg-RX-API-DMAC7.html)
SI (1) SI1313703T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002016321A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300894B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408506A (pt) * 1994-01-31 1997-08-05 Pfizer Compostos neuroprotetores
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
CA2419279C (en) 2008-10-14
HUP0301548A3 (en) 2010-03-29
EP1313703A1 (en) 2003-05-28
JO2289B1 (en) 2005-09-12
NO324941B1 (no) 2008-01-07
KR20030022417A (ko) 2003-03-15
CA2419279A1 (en) 2002-02-28
SI1313703T1 (sl) 2008-06-30
RU2272027C2 (ru) 2006-03-20
DE60132782T2 (de) 2009-02-05
KR100589991B1 (ko) 2006-06-15
EP1313703B1 (en) 2008-02-13
CZ303319B6 (cs) 2012-08-01
YU13003A (sh) 2006-05-25
JP4162991B2 (ja) 2008-10-08
NZ523990A (en) 2004-09-24
PL361387A1 (en) 2004-10-04
CN1447793A (zh) 2003-10-08
AU2001285894B2 (en) 2006-06-15
HRP20030125A2 (en) 2005-02-28
BR0113348A (pt) 2003-07-08
US6407235B1 (en) 2002-06-18
ZA200300894B (en) 2004-04-30
JP2004506715A (ja) 2004-03-04
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
AR030373A1 (es) 2003-08-20
MA26947A1 (fr) 2004-12-20
AU8589401A (en) 2002-03-04
HK1059083A1 (en) 2004-06-18
DK1313703T3 (da) 2008-05-19
PL204215B1 (pl) 2009-12-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
NO20030781D0 (no) 2003-02-19
CZ2003492A3 (cs) 2004-01-14
ES2299508T3 (es) 2008-06-01
MXPA03001311A (es) 2003-06-30
WO2002016321A1 (en) 2002-02-28
PA8525601A1 (es) 2002-04-25
HUP0301548A2 (hu) 2003-08-28
NO20030781L (no) 2003-02-19
DE60132782D1 (de) 2008-03-27
CY1107937T1 (el) 2013-09-04
US20020040037A1 (en) 2002-04-04
ATE386022T1 (de) 2008-03-15
MY136065A (en) 2008-08-29
HU229802B1 (hu) 2014-07-28
IL154254A0 (en) 2003-09-17
HRP20030125B1 (en) 2011-07-31
ECSP034489A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
CR20230496A (es) Compuestos heterocíclicos
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
PE20020272A1 (es) N-oxidos de derivados de 4-fenil-piridina como prodrogas de los antagonistas del receptor de neuroquinina 1 (nk-1)
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
PE20011228A1 (es) Derivados de piridopirimidina o iminopirimidina utiles para el tratamiento de enfermedades neurodegenerativas
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
PE20070051A1 (es) Serin-amidas sustituidas con heteroaroilo
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
PE20221420A1 (es) Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida
MX2019000035A (es) Composicion de amina util para producir espuma de poliuretano.
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
CL2021000171A1 (es) Procedimiento y productos intermedios para la preparación de bilastina
MX2020013827A (es) Proceso de preparacion de compuestos triciclicos.
ES2046671T3 (es) Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-tionas.
EG15346A (en) Novel arylamine derivatives,production thereof and use thereof as microbicides
TW200724535A (en) Oxazine disulfide dyes
AR006876A1 (es) Procedimiento e intermedios para preparar el compuesto {2-(2-[1,2,4]- triazol-3-ilmetil)-1,2,3,4-tetrahidroisoquinolin-6-il} amida del acido 4'-trifluorometilbifenil-2-carboxilico
AR004015A1 (es) Procedimiento para preparar compuestos de quinolina o sales farmaceuticamente aceptables de los mismos, y compuestos intermediarios
AR133754A1 (es) Compuestos, composiciones y métodos
AR043245A1 (es) Composicion insecticida de incienso y emulsion y procedimiento para prepararla
NZ335105A (en) Process for alkylating hindered sulfonamides
AR030373A1 (es) Profarmacos para el tratamiento de enfermedades relacionadas con el receptor del nmda
UY40683A (es) Oxazolidinonas e imidazolinonas sustituidas como herbicidas
PE20051059A1 (es) Concentrados de aditivos para carburantes y lubricantes, que contienen por lo menos un derivado de antraquinona como sustancia marcadora

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed